annual CFF:
$12.13M-$341.39M(-96.57%)Summary
- As of today (July 1, 2025), XENE annual cash flow from financing activities is $12.13 million, with the most recent change of -$341.39 million (-96.57%) on December 31, 2024.
- During the last 3 years, XENE annual CFF has fallen by -$435.41 million (-97.29%).
- XENE annual CFF is now -97.29% below its all-time high of $447.54 million, reached on December 31, 2021.
Performance
XENE Cash from financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly CFF:
$1.15M-$10.98M(-90.51%)Summary
- As of today (July 1, 2025), XENE quarterly cash flow from financing activities is $1.15 million, with the most recent change of -$10.98 million (-90.51%) on March 31, 2025.
- Over the past year, XENE quarterly CFF has increased by +$1.15 million (+100.00%).
- XENE quarterly CFF is now -99.64% below its all-time high of $324.01 million, reached on December 31, 2023.
Performance
XENE quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM CFF:
$13.28M+$1.15M(+9.49%)Summary
- As of today (July 1, 2025), XENE TTM cash flow from financing activities is $13.28 million, with the most recent change of +$1.15 million (+9.49%) on March 31, 2025.
- Over the past year, XENE TTM CFF has dropped by -$340.24 million (-96.24%).
- XENE TTM CFF is now -97.81% below its all-time high of $606.48 million, reached on June 30, 2022.
Performance
XENE TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash from financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
XENE Cash from financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -96.6% | +100.0% | -96.2% |
| 3 y3 years | -97.3% | -85.4% | -96.1% |
| 5 y5 years | -55.9% | -98.9% | -88.3% |
XENE Cash from financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -97.3% | at low | -99.6% | >+9999.0% | -97.8% | +9.5% |
| 5 y | 5-year | -97.3% | at low | -99.6% | +106.9% | -97.8% | +9.5% |
| alltime | all time | -97.3% | +376.3% | -99.6% | +106.9% | -97.8% | +1125.6% |
XENE Cash from financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2025 | - | $1.15M(-90.5%) | $13.28M(+9.5%) |
| Dec 2024 | $12.13M(-96.6%) | $12.13M(>+9900.0%) | $12.13M(-96.3%) |
| Sep 2024 | - | $0.00(0.0%) | $324.01M(-8.3%) |
| Mar 2024 | - | $0.00(-100.0%) | $353.52M(0.0%) |
| Dec 2023 | $353.52M(+27.0%) | $324.01M(+998.1%) | $353.52M(+1097.8%) |
| Sep 2023 | - | $29.51M(>+9900.0%) | $29.51M(-89.4%) |
| Dec 2022 | $278.47M(-37.8%) | $6000.00(-99.1%) | $278.47M(-53.8%) |
| Sep 2022 | - | $699.00K(-99.7%) | $602.42M(-0.7%) |
| Jun 2022 | - | $269.89M(+3326.7%) | $606.48M(+80.1%) |
| Mar 2022 | - | $7.88M(-97.6%) | $336.70M(-24.8%) |
| Dec 2021 | $447.54M(+421.6%) | $323.95M(+6708.6%) | $447.54M(+262.0%) |
| Sep 2021 | - | $4.76M(+4186.5%) | $123.64M(+4.0%) |
| Jun 2021 | - | $111.00K(-99.9%) | $118.88M(+16.5%) |
| Mar 2021 | - | $118.72M(>+9900.0%) | $102.05M(+18.9%) |
| Dec 2020 | $85.80M(+211.8%) | $45.00K(>+9900.0%) | $85.80M(-24.2%) |
| Sep 2020 | - | $0.00(-100.0%) | $113.18M(-0.0%) |
| Jun 2020 | - | -$16.72M(-116.3%) | $113.20M(-12.9%) |
| Mar 2020 | - | $102.47M(+273.6%) | $129.93M(+372.2%) |
| Dec 2019 | $27.52M(-75.3%) | $27.43M(>+9900.0%) | $27.52M(>+9900.0%) |
| Sep 2019 | - | $18.00K(+63.6%) | $121.00K(-99.8%) |
| Jun 2019 | - | $11.00K(-81.0%) | $77.53M(-30.5%) |
| Mar 2019 | - | $58.00K(+70.6%) | $111.53M(-0.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2018 | $111.59M(+1478.4%) | $34.00K(-100.0%) | $111.59M(-5.8%) |
| Sep 2018 | - | $77.43M(+127.7%) | $118.45M(+188.8%) |
| Jun 2018 | - | $34.01M(>+9900.0%) | $41.02M(+484.8%) |
| Mar 2018 | - | $119.00K(-98.3%) | $7.01M(-0.8%) |
| Dec 2017 | $7.07M(-70.5%) | $6.89M(>+9900.0%) | $7.07M(+3042.2%) |
| Sep 2017 | - | $0.00(-100.0%) | $225.00K(-99.1%) |
| Jun 2017 | - | $3000.00(-98.3%) | $24.06M(-0.1%) |
| Mar 2017 | - | $174.00K(+262.5%) | $24.09M(+0.5%) |
| Dec 2016 | $23.96M(+8520.1%) | $48.00K(-99.8%) | $23.96M(+0.0%) |
| Sep 2016 | - | $23.83M(>+9900.0%) | $23.95M(>+9900.0%) |
| Jun 2016 | - | $38.00K(-13.6%) | $147.00K(-24.6%) |
| Mar 2016 | - | $44.00K(+15.8%) | $195.00K(-29.9%) |
| Dec 2015 | $278.00K(-99.3%) | $38.00K(+40.7%) | $278.00K(-99.3%) |
| Sep 2015 | - | $27.00K(-68.6%) | $42.66M(+1.4%) |
| Jun 2015 | - | $86.00K(-32.3%) | $42.06M(+1.0%) |
| Mar 2015 | - | $127.00K(-99.7%) | $41.64M(+1.3%) |
| Dec 2014 | $41.12M(-1036.6%) | $42.42M(-7555.0%) | $41.12M(-3275.6%) |
| Sep 2014 | - | -$569.00K(+70.9%) | -$1.29M(+78.4%) |
| Jun 2014 | - | -$333.00K(-15.3%) | -$726.00K(+84.7%) |
| Mar 2014 | - | -$393.00K | -$393.00K |
| Dec 2013 | -$4.39M(<-9900.0%) | - | - |
| Dec 2012 | $0.00(-100.0%) | - | - |
| Dec 2011 | $2000.00 | - | - |
FAQ
- What is Xenon Pharmaceuticals annual cash flow from financing activities?
- What is the all time high annual CFF for Xenon Pharmaceuticals?
- What is Xenon Pharmaceuticals annual CFF year-on-year change?
- What is Xenon Pharmaceuticals quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Xenon Pharmaceuticals?
- What is Xenon Pharmaceuticals quarterly CFF year-on-year change?
- What is Xenon Pharmaceuticals TTM cash flow from financing activities?
- What is the all time high TTM CFF for Xenon Pharmaceuticals?
- What is Xenon Pharmaceuticals TTM CFF year-on-year change?
What is Xenon Pharmaceuticals annual cash flow from financing activities?
The current annual CFF of XENE is $12.13M
What is the all time high annual CFF for Xenon Pharmaceuticals?
Xenon Pharmaceuticals all-time high annual cash flow from financing activities is $447.54M
What is Xenon Pharmaceuticals annual CFF year-on-year change?
Over the past year, XENE annual cash flow from financing activities has changed by -$341.39M (-96.57%)
What is Xenon Pharmaceuticals quarterly cash flow from financing activities?
The current quarterly CFF of XENE is $1.15M
What is the all time high quarterly CFF for Xenon Pharmaceuticals?
Xenon Pharmaceuticals all-time high quarterly cash flow from financing activities is $324.01M
What is Xenon Pharmaceuticals quarterly CFF year-on-year change?
Over the past year, XENE quarterly cash flow from financing activities has changed by +$1.15M (+100.00%)
What is Xenon Pharmaceuticals TTM cash flow from financing activities?
The current TTM CFF of XENE is $13.28M
What is the all time high TTM CFF for Xenon Pharmaceuticals?
Xenon Pharmaceuticals all-time high TTM cash flow from financing activities is $606.48M
What is Xenon Pharmaceuticals TTM CFF year-on-year change?
Over the past year, XENE TTM cash flow from financing activities has changed by -$340.24M (-96.24%)